Skip to main content
. 2013 Apr 25;8(4):e61520. doi: 10.1371/journal.pone.0061520

Figure 3. PARP1 depletion by siRNA causes PARP inhibitor resistance in human cells.

Figure 3

CAL51 (A, B) or DLD1 (C, D) cells were transfected with the indicated siRNAs and treated with BMN 673 (A, C) or olaparib (B, D). Cell survival assayed using CellTiter Glo and expressed as a proportion of DMSO-treated control is shown on the y-axes. Allstar, siCONT1, siCONT2 are non-targeting siRNA controls. siRNA targeting BRCA2 is included as a positive control known to sensitise cells to PARP inhibition [8]. The mean of five replicates is shown; error bars show SEM. **, P<0.01; ***, P<0.001 for PARP1 compared to non-targeting control (two-way ANOVA with Bonferroni post test). E Confirmation of knockdown of PARP1 protein. Lysates from CAL51 cells transfected with the indicated siRNAs were probed with anti-PARP1 (top) or anti-β-actin (bottom).